Truseltiq (infigratinib)

News alerts, weekly reports and conference planners

Company:

BridgeBio, Juniper Bio, Kyowa Kirin, LianBio, Novartis, Pfizer, Xediton Pharma

Drug class:

FGFR inhibitor

Related drugs:

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B
FGFR2 fusion	Solid Tumor	FGFR2 fusion	Solid Tumor	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Glioma	FGFR2 fusion	Glioma	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Gastric Cancer	FGFR2 fusion	Gastric Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Breast Cancer	FGFR2 fusion	Breast Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR2 fusion	Hepatocellular Cancer	FGFR2 fusion	Hepatocellular Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Bladder Cancer	FGFR1 amplification	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Breast Cancer	FGFR3 mutation	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Gastroesophageal Junction Adenocarcinoma	FGFR2 amplification	Gastroesophageal Junction Adenocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 R248C	Urothelial Cancer	FGFR3 R248C	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3 V443L	Urothelial Cancer	FGFR3 V443L	Urothelial Cancer	infigratinib Resistant: C3 – Early Trials infigratinib Resistant : C3	infigratinib Resistant: C3 – Early Trials infigratinib Resistant : C3
FGFR3 V443M	Urothelial Cancer	FGFR3 V443M	Urothelial Cancer	infigratinib Resistant: C3 – Early Trials infigratinib Resistant : C3	infigratinib Resistant: C3 – Early Trials infigratinib Resistant : C3
FGFR3 L496V	Urothelial Cancer	FGFR3 L496V	Urothelial Cancer	infigratinib Resistant: C3 – Early Trials infigratinib Resistant : C3	infigratinib Resistant: C3 – Early Trials infigratinib Resistant : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3 G380R	Urothelial Cancer	FGFR3 G380R	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3 Y375C	Urothelial Cancer	FGFR3 Y375C	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	infigratinib + PD173074 Sensitive: C3 – Early Trials infigratinib + PD173074 Sensitive : C3	infigratinib + PD173074 Sensitive: C3 – Early Trials infigratinib + PD173074 Sensitive : C3
FGFR2-AHCYL1 fusion	Cholangiocarcinoma	FGFR2-AHCYL1 fusion	Cholangiocarcinoma	infigratinib + PD173074 Sensitive: C3 – Early Trials infigratinib + PD173074 Sensitive : C3	infigratinib + PD173074 Sensitive: C3 – Early Trials infigratinib + PD173074 Sensitive : C3
FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR2-OPTN fusion	Cholangiocarcinoma	FGFR2-OPTN fusion	Cholangiocarcinoma	infigratinib Resistant: C4 – Case Studies infigratinib Resistant : C4	infigratinib Resistant: C4 – Case Studies infigratinib Resistant : C4
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	infigratinib Resistant: C4 – Case Studies infigratinib Resistant : C4	infigratinib Resistant: C4 – Case Studies infigratinib Resistant : C4

Truseltiq (infigratinib)

Associations
(53)

Associations
(53)

Truseltiq (infigratinib)

Associations(53)

Associations(53)

Associations
(53)

Associations
(53)